Clinical trial registry changes: April 2026

Among the trials TrialRedline tracks, 90 changed their ClinicalTrials.gov record in April 2026: 4 status changes to terminated, withdrawn or suspended, 19 primary outcome text edits, 27 completion dates moved later, 2 completion dates moved earlier, 25 enrollment changes, 43 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.

90Trials with a recorded change
90Registry updates
75Sponsors

Trials terminated, withdrawn or suspended

4 in April 2026. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.

Primary outcome text edits

19 in April 2026. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of adverse events. After: Measure: Number of Subjects Experiencing Any Adverse Event.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Minimal residual disease negativity rate. After: Measure: Minimal Residual Disease Negative CR Rate.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: The frequency and severity of treatment emergent adverse events (TEAEs), discontinuations due to adverse events (AEs), and laboratory abnormalities after dosing with AB-729 plus Peg-IFNα-2a. After: Measure: The Frequency and Severity of Treatment Emergent Adverse Events (TEAEs), Discontinuations Due to AEs and Lab Abnormalities After Dosing With AB-729 Plus Peg-IFNα-2a.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change From Baseline in Angina Frequency Measure: Change From Baseline in CCS Angina Class Measure: Change From Baseline in Total Exercise Time Measure: Change From Baseline in Health-related Quality of Life (HRQoL). After: Measure: Change From Baseline in Number of Angina Attacks Per Week Measure: Change From Baseline in CCS Angina Class Measure: Change From Baseline in Total Exercise Time Measure: Change From Baseline in Health-related Quality of Life (HRQoL).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of participants with adverse events (AEs). After: Measure: Number of Subjects With Serious Adverse Events.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Ocular itching evaluated by the Subject.. After: Measure: Subject-Reported Ocular Itching Score Assessed in the Allergy Chamber.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.. After: Measure: Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer..

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: All-cause Mortality. After: Measure: Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular Complications.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from baseline in daily average nausea severity scores from the Gastroparesis Core Symptom Daily Diary (GCS-DD). After: Measure: Change From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT Population.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Overall survival (OS) Measure: Progression free survival (PFS) as assessed by using RANO-HGG criteria. After: Measure: Overall survival (OS).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Overall Survival. After: Measure: Overall Survival: All Randomized Population Measure: Overall Survival: Stratified by Histology - Squamous vs. Non-Squamous.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT) Measure: To assess the safety and tolerability of AMX0035 administered orally for up to 144 weeks in adult participants with Wolfram syndrome. After: Measure: To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT) Measure: To assess the safety and tolerability of AMX0035 administered orally for up to 208 weeks in adult participants with Wolfram syndrome.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change From Baseline in the Modified Friedreich Ataxia Rating Scale (mFARS) Score at Week 72. After: Measure: Change From Baseline in the mFARS Score at Week 72 - Modified Intent-to-treat (mITT) Analysis Set Measure: Change From Baseline in the mFARS Score at Week 72 - Intent-to-treat (ITT) Analysis Set.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: MBC substudy: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment. After: Measure: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Mean % change in BMI. After: Measure: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Overall Survival (OS). After: Measure: Overall Survival (OS) Measure: Progression-Free Survival (PFS).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline for KYV-101 Treatment Arm to Standard of Care Arm (Phase 3) Measure: Efficacy of KYV-101 via Quantitative Myasthenia Gravis (QMG) change from baseline for KYV-101 Treatment arm to Standard of Care arm. After: Measure: Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3) Measure: Efficacy of KYV-101 via Quantitative Myasthenia Gravis (QMG) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To evaluate the efficacy of leronlimab in combination with trifluridine and tipiracil + bevacizumab in participants with CCR5+, refractory, MSS, mCRC.. After: Measure: The efficacy of leronlimab in combination with trifluridine and tipiracil + bevacizumab in participants with relapsed, refractory, MSS, mCRC..

Check registry source

Completion dates moved later

27 in April 2026. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.

Showing 25 of 27. Browse all tracked trials to open the rest.

Completion dates moved earlier

2 in April 2026. Primary completion date moved earlier while its type stayed the same. Largest move first.

Enrollment changes

25 in April 2026. The participant count changed. Planned and actual counts are shown as recorded. Newest first.

Other recruitment status changes

43 in April 2026. Any other change of recruitment status, such as recruiting to completed. Newest first.

Showing 25 of 43. Browse all tracked trials to open the rest.

Cite this report

TrialRedline, “Clinical trial registry changes: April 2026”. https://trialredline.com/reports/2026-04

Based on public ClinicalTrials.gov record history. How we collect and check the data